detection antibody against human vegf a  (R&D Systems)

Journal: Cancers

Article Title: Local Magnetic Hyperthermia and Systemic Gemcitabine/Paclitaxel Chemotherapy Triggers Neo-Angiogenesis in Orthotopic Pancreatic Tumors without Involvement of Auto/Paracrine Tumor Cell VEGF Signaling and Hypoxia

doi: 10.3390/cancers16010033

Figure Lengend Snippet: Magnetic hyperthermia combined with chemotherapy decreased intratumoral angiogenesis in residual pancreatic tumors. Semi-quantitative evaluation of intratumoral markers: ( a ) VEGF, ( b ) VEGFR2, ( c ) Neuropilin 1, ( d ) Ki67, and ( e ) phosphorylated ERK (pERK). Each bar represents mean ± SEM. Eight images were quantified per treatment group ( n = 2 mice/group). Rel. = relative: Positively stained cells computed relative to the nuclei number in a ROI stained with hematoxylin using the Image-J software. ( f ) Representative histological micrographs of tumor tissue slices, scale bar: 20 µm. Animal groups: MHsC = magnetic hyperthermia + chemotherapy, MH = magnetic hyperthermia, sC = systemic chemotherapy, M = MNP alone, and N = non-treated. * p < 0.05, ** p < 0.01, **** p < 0.0001.

Article Snippet: These were incubated with primary antibodies against human VEGFR2 (1:800, Cell Signaling Technology Inc., Danvers, MA, USA), mice CD31 (PECAM-1, 1:200, Cell Signaling Technology Inc., MA, USA), human/mouse HIF-1α (1:100, Cell Signaling Technology Inc., MA, USA), human Neuropilin-1, human α v β 3 integrin (1:200, Abcam plc, Cambridge, UK), human VEGF (1:100, Invitrogen, Thermo Fisher Scientific, Waltham, MA, USA), or Ki67 (1:500, Abcam plc, Cambridge, UK), followed by incubation with a biotin-labeled secondary antibody (goat anti-rabbit IgG (H + L), 1:2250, Dianova GmbH, Hamburg, Germany) or with a peroxidase-labeled polymer secondary antibody (DAKO, Glostrup, Denmark).

Techniques: Staining, Software